Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort
- 1 June 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 21 (10), 1283-1291
- https://doi.org/10.1097/qad.0b013e3280b07b5b
Abstract
To investigate the effect of a short course of HAART during primary HIV infection (PHI) on rate of CD4 cell and viral load change.Data following HAART cessation from 89 individuals (seroconverting 1999-2003) who chose to take a 3 month course of HAART at PHI were compared with 179 untreated controls in CASCADE, using linear and nonlinear random effects models. Participants were non-randomized but frequency matched for age, sex, risk factor, year of seroconversion and presentation within the first 6 months of seroconversion. Time to CD4 cell count < 350 cells/microl and initiation of clinically indicated antiretroviral therapy (ART) were also compared as competing risks.The rate of CD4 cell decline following therapy cessation appeared significantly slower among treated participants than untreated controls: losses of 51 cells/microl [95% confidence interval (CI), 32-69] and 77 cells/microl (95% CI, 65-89), respectively, 3 years after seroconversion (P = 0.011). Based on extrapolated data, viral loads also differed significantly at this point (4.09 and 4.53 copies/ml, respectively). At 2 years, there was no significant difference in mean viral load levels: 4.31 copies/ml (95% CI, 4.14-4.48) and 4.47 copies/ml (95% CI, 4.28-4.66), respectively. CASCADE seroconverters were more likely to reach CD4 cell count < 350 cells/microl or initiate clinically indicated ART (hazard ratio, 1.45; 95% CI, 1.02-2.05; P = 0.039).A short course of ART at PHI may delay CD4 cell decline. Confirmation of this requires a randomized clinical trial powered to address definitively the role of ART intervention in PHI (currently underway through SPARTAC).Keywords
This publication has 38 references indexed in Scilit:
- Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functionsAIDS, 2005
- Rapid Clearance of Virus after Acute HIV‐1 Infection: Correlates of Risk of AIDSThe Journal of Infectious Diseases, 2004
- Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?AIDS, 2004
- Immune control of HIV-1 after early treatment of acute infectionNature, 2000
- Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- The Risk of Disease Progression Is Determined during the First Year of Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1998
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences, 1997
- Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of ViremiaScience, 1997
- Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV DiseaseScience, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995